Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966709 | 0.96 | KDM4E (0.33) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL1256152 | 0.92 | KDM4E (0.35) | KDM4EALDH1A1MAPTBLMCNR2 | |
| SCHEMBL25831470 | 0.82 | KDM4E (0.30) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL23966775 | 0.81 | KDM4E (0.33) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL24410809 | 0.78 | KDM4E (0.32) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL13391770 | 0.75 | — | — | |
| SCHEMBL24072577 | 0.74 | TRPM8 (0.38) | KDM4EALDH1A1MAPT | |
| SCHEMBL23982644 | 0.73 | KDM4E (0.30) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL24096703 | 0.73 | — | — | |
| SCHEMBL25800378 | 0.72 | SMN1; SMN2 (0.36) | ALDH1A1MAPTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240738-B1 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | LILLY CO ELI (US) | 2025-05-07 | — | — | EP | disclosed |
| US-11970485-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| EP-4240738-A1 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | Eli Lilly and Company (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| CN-116438179-A | Pyrazole derivatives as RET kinase inhibitors | 伊莱利利公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2022098970-A9 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220144816-A1 | RET KINASE INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| WO-2022098970-A1 | PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2012019015-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
| CN-101801383-A | Kinase inhibitors for the treatment of myeloproliferative and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC | 2010-08-11 | — | — | CN | disclosed |
| EP-2146716-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-01-27 | — | — | EP | disclosed |
| CN-101553232-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008131227-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970485-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | KDM4E 1642/4885ALDH1A1 1205/4885MAPT 2324/4885 |
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRAF, PRKDC, RAF1 | KDM4E 2009/4885ALDH1A1 1389/4885MAPT 1608/4885 |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | KDM4E 3402/4885ALDH1A1 3395/4885MAPT 3875/4885 |
| US-11697647-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | KDM4E 1642/4885ALDH1A1 1205/4885MAPT 2324/4885 |
| US-20230265085-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | KDM4E 1642/4885ALDH1A1 1205/4885MAPT 2324/4885 |
| US-20220144816-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | KDM4E 1642/4885ALDH1A1 1205/4885MAPT 2324/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | KDM4E 1040/4885ALDH1A1 2292/4885MAPT 2853/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | KDM4E 2009/4885ALDH1A1 1389/4885MAPT 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.